| Outcome: increase in take-home doses | Outcome: decrease in in-person counseling requirement | ||
---|---|---|---|---|
Univariate association OR [95%CI] | Controlled for methadone treatment length OR [95%CI] | Univariate association OR [95%CI] | Controlled for methadone treatment length OR [95%CI] | |
Age | ||||
30–39 vs < 30 | 0.97 [0.56, 1.67] | 0.84 [0.47, 1.50] | 1.62 [0.85, 3.04] | 1.52 [0.78, 2.93] |
40–49 vs < 30 | 0.74 [0.39, 1.40] | 0.63 [0.31, 1.24] | 0.89 [0.44, 1.80] | 0.81 [0.38, 1.70] |
50 + vs < 30 | 1.58 [0.68, 3.77] | 1.28 [0.51, 3.31] | 0.82 [0.33, 2.10] | 0.79 [0.29, 2.21] |
Gender | ||||
Female vs Male | 1.35 [0.79, 2.35] | 1.35 [0.78, 2.35] | 0.82 [0.41, 1.53] | 0.82 [0.41, 1.55] |
Other vs Male | 1.01 [0.36, 2.76] | 0.99 [0.35, 2.74] | 0.54 [0.18, 1.65] | 0.53 [0.18, 1.62] |
Cost | ||||
20 – 99$ vs < 20$ | 0.57 [0.17, 1.75] | 0.50 [0.15, 1.58] | 1.34 [0.34, 8.84] | 1.25 [0.32, 8.30] |
100 – 199$ vs < 20$ | 0.73 [0.32, 1.62] | 0.60 [0.25, 1.37] | 0.23 [0.10, 0.52] | 0.20 [0.08, 0.46] |
 > 200$ vs < 20$ | 0.85 [0.52, 1.39] | 0.78 [0.47, 1.28] | 0.55 [0.32, 0.95] | 0.51 [0.29, 0.89] |
Region | ||||
Northeast vs Midwest | 1.31 [0.72, 2.37] | 1.31 [0.72, 2.39] | 2.61 [1.22, 5.84] | 2.54 [1.18, 5.70] |
South vs Midwest | 1.24 [0.72, 2.14] | 1.27 [0.74, 2.19] | 0.92 [0.50, 1.65] | 0.94 [0.51, 1.70] |
West vs Midwest | 0.61 [0.25, 1.41] | 0.64 [0.26, 1.49] | 0.71 [0.29, 1.80] | 0.71 [0.29 1.83] |
Length on methadone treatment | ||||
1–5 years vs < 1 year | 1.51 [0.73, 3.19] | – | 1.07 [0.45, 2.37] | – |
5–10 years vs < 1 year | 1.57 [0.74, 3.41] | – | 1.30 [0.53, 3.04] | – |
 > 10 years vs < 1 year | 2.01 [0.93, 4.41] | – | 1.16 [0.47, 2.73] | – |